Clinical trial
Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00036088 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00036088 |
|---|---|
| Title | Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Olanzapine |
| Enrollment | 530 |
| Start date | Aug 1, 2001 |
| Completion | Jul 1, 2002 |
| First posted | May 8, 2002 |
| Last update posted | Jul 19, 2006 |
| Countries | Argentina, Austria, Brazil, Germany, Ireland, Mexico, Peru, Puerto Rico, Spain, United Kingdom, United States, Venezuela |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: